Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0006632003
Thu, 10.03.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 10, 2022
Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT).
MorphoSys' Management team will host a conference ca [ … ]
Mon, 24.01.2022
MorphoSys AG
MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
MorphoSys AG (FSE: MOR; NASDAQ: MOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European hea [ … ]
Mon, 10.01.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 10, 2022
MorphoSys To Present At the 40th Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; NASDAQ: MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at [ … ]
Fri, 07.01.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 07, 2022
MorphoSys Reports Preliminary 2021 Monjuvi U.S. Sales and Provides 2022 Financial Guidance
- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million (€ 66.9 million)
- Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million
MorphoSys AG (FSE: MOR; [ … ]
Sun, 12.12.2021
MorphoSys AG
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Data presented during poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition
Latest results from the MANIFEST trial underscore the rationale to further explore pelabres [ … ]
Sat, 11.12.2021
MorphoSys AG
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recomm [ … ]
Mon, 29.11.2021
MorphoSys AG
Media Release
Planegg/Munich, Germany, November 29, 2021
MorphoSys AG: Corporate Calendar 2022
Dear Madam/Sir,
Please note MorphoSys' financial reporting dates 2022 as follows:
Publication of Interim Statement / Report
Conference Call
Year-End Results 2021
March 16, 2022 // 10 pm CET
(5 pm EDT; 9 pm GMT)
March 17, 2022 // [ … ]
Wed, 10.11.2021
MorphoSys AG
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q
- Ten abstracts, including two oral presentations, accepted at upcoming ASH
- Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data
- Felzartamab demonstrated proo [ … ]
Tue, 09.11.2021
MorphoSys AG
Media Release
MorphoSys Announces Departure of Roland Wandeler
Planegg/Munich, Germany, November 9, 2021 - MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursu [ … ]
Thu, 04.11.2021
MorphoSys AG
MorphoSys presents interim results from M-PLACE study with felzartamab during American Society of Nephrology Annual MeetingFelzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy
MorphoSys AG (FSE: MOR; NASDAQ: MOR) presented interim results from the M- [ … ]